CML and muscle function

Chronic myeloid leukemia (CML) became a disease with a good prognosis since the application of the targeted tyrosine kinase inhibitors (TKI) therapy since 2000. However, musculoskeletal pain/myalgia is a frequently reported adverse drug reaction of TKIs (80% of patients reporting an adverse drug reaction, report muscle complaints), contributing to poor drug adherence. Little research has been done on the pathogenesis and clinical management of musculoskeletal problems during TKI therapy. This is of outmost importance since: i) the onset of musculoskeletal problems contributes to the poor adherence to TKI therapy and ii) continuous, potentially lifelong treatment with TKIs is required for CML chronic phase (CP) disease control which impacts quality of life. Therefore, this study will investigate whether differences exist in muscle function, muscle energy metabolism and cardiorespiratory fitness in CML CP patients using TKI’s with muscle complaints, compared to CML CP patients using TKI’s without muscle complaints, and controls.

Cross-sectional

None